甲状腺功能亢进症放射性碘治疗后的癌症风险:一项队列研究
这项历史性队列研究利用Clalit医疗数据库,纳入2002-2015年新诊断并接受131I或硫酰胺类治疗的成人甲亢患者,排除既往恶性肿瘤者。中位随访共123,166人年,多变量分析未发现放射性碘治疗与总体癌症风险相关(HR=1.01,95%CI 0.83-1.21,p=0.95),但随访前4.2年内 sensitivity analysis 显示总体癌症风险升高(HR=2.11,95%CI 1.59-2.80,p<0.0001),非霍奇金淋巴瘤仅在单变量分析中显著(HR=2.89,95%CI 1.12-7.46,p=0.03),多变量分析未达显著(HR=2.32,95%CI 0.88-6.13,p=0.09)。
要点
- 多变量分析未发现放射性碘治疗与总体癌症风险相关(HR=1.01,95%CI 0.83-1.21)。
- 随访前4.2年内 sensitivity analysis 显示总体癌症风险升高(HR=2.11,95%CI 1.59-2.80)。
- 非霍奇金淋巴瘤风险仅在单变量分析中显著(HR=2.89,95%CI 1.12-7.46)。
核心结论
- 长期随访中未发现甲亢放射性碘治疗与总体癌症发生风险相关。
- 特定癌症分析中,仅单变量分析显示与非霍奇金淋巴瘤风险有统计学显著关联。
研究设计与样本
- 历史性队列研究,使用Clalit医疗数据库。
- 纳入2002-2015年新诊断甲亢且新接受131I或硫酰胺类(丙硫氧嘧啶/甲巯咪唑)治疗的成人,排除既往恶性肿瘤者。
- 共16,637例患者,随访123,166人年。
- 采用倾向性评分计算接受放射性碘治疗的概率,并用于多变量Cox比例风险模型。
主要发现
- 总体癌症风险:单变量分析HR=0.99(95%CI 0.83-1.19,p=0.91),多变量分析HR=1.01(95%CI 0.83-1.21,p=0.95)。
- sensitivity analysis中随访前4.2年内总体癌症风险HR=2.11(95%CI 1.59-2.80,p<0.0001),更长随访期未发现风险增加。
- 非霍奇金淋巴瘤:单变量分析HR=2.89(95%CI 1.12-7.46,p=0.03),多变量分析HR=2.32(95%CI 0.88-6.13,p=0.09)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Radioactive iodine (131I) is in widespread use for the treatment of hyperthyroidism. Data on long-term safety outcome are limited and conflicting. The objectives of this study were to evaluate the association of radioiodine treatment for hyperthyroidism with overall cancer and with specific cancer types. Methods: This is a historical cohort study, using the Clalit health care database. Participants were all adults with a new diagnosis of hyperthyroidism in 2002-2015, newly treated with 131I, or with thionamides (propylthiouracil/thiamazole), excluding patients with previous malignancies. Age, sex, smoking history, body mass index, Clalit district, socioeconomic status, history of diabetes mellitus and of hypertension, use of aspirin and of statins, and adherence to cancer screening procedures were used to calculate propensity score to receive radioiodine. Incidence rates and 95% confidence intervals (CIs) were calculated for overall cancer occurrence, and for each cancer type using Poisson distribution. Association between study variables and time to cancer event was evaluated using cause-specific hazard ratios (HR) and CIs, estimated by univariate and propensity score adjusted multivariate Cox proportional hazards models. For sensitivity analysis we stratified the cohort by calendar year at cohort entry and by length of follow-up. Results: A total of 16,637 patients formed the study cohort, with 123,166 person-years of follow-up. There was no association between radioiodine treatment and increased risk of overall cancer (HR = 0.99 [CI 0.83-1.19], p = 0.91; HR = 1.01 [CI 0.83-1.21], p = 0.95) in univariate and multivariate analyses, respectively. However, in a sensitivity analysis, we found an association with overall cancer risk in the first period of follow-up (up to 4.2 years) (HR = 2.11 [CI 1.59-2.80], p < 0.0001), and no association with increased risk in a longer follow-up period. An association was found between radioiodine exposure and an increased risk for non-Hodgkin's lymphoma (NHL) in univariate but a nonsignificant increased risk in multivariate analysis: HR = 2.89 [CI 1.12-7.46], p = 0.03; HR = 2.32 [CI 0.88-6.13], p = 0.09, respectively. Conclusions: No association was found between radioiodine treatment for hyperthyroidism and risk for incident cancer in long-term follow-up. In an analysis of specific cancer types, a statistically significant association was found with NHL only in univariate analysis.
引用
- Gronich N, Lavi I, Rennert G, et al. Cancer Risk After Radioactive Iodine Treatment for Hyperthyroidism: A Cohort Study. Thyroid. 2020. PMID: 31880205. doi:10.1089/thy.2019.0205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。